Prywatna Praktyka Lekarska Prof. Dr Hab. Med. Paweł Hrycaj
- Address
- ul. Os. Rzeczyposp olitej 6,, 61-397 Poznan, Poland
Immune System Diseases
The site focuses on Primary Sjogren’s Disease, an autoimmune condition affecting exocrine glands, by testing innovative therapies aimed at reducing systemic disease activity.
- Evaluation of novel biologic agents for autoimmune disease
- Assessment of disease activity using clinical scoring systems
- Monitoring safety and tolerability in patients with moderate‑to‑severe disease
These studies aim to improve treatment options for patients with severe systemic involvement, offering hope for better disease control.
Immune System Phenomena
Research explores immune system phenomena underlying Sjögren’s syndrome, particularly the mechanisms driving systemic inflammation.
- Investigation of immune cell activation patterns
- Identification of biomarkers linked to disease activity
- Analysis of cytokine networks influencing systemic symptoms
By clarifying these processes, the trials support the development of more precise therapeutic strategies for autoimmune disorders.
Immune System Processes
The clinic examines immune system processes targeted by agents such as IMVT-1402 and dazodalibep to alleviate systemic manifestations of Sjögren’s syndrome.
- Impact of targeted therapy on systemic manifestations
- Correlation of clinical scores with treatment response
- Long‑term safety evaluation of emerging agents
Findings are intended to guide clinicians in selecting effective interventions for patients with severe disease activity.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Immunovant Sciences GmbH1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Prywatna Praktyka Lekarska Prof. Dr Hab. Med. Paweł Hrycaj
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity | Immunovant Sciences GmbH | Phase II | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dazodalibep | 1 | Unknown | 2024-06-07 | 2024-06-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.